Loading clinical trials...
Loading clinical trials...
A Phase 2, Open-Label Study to Evaluate the Performance and Safety of ONM100, an Intraoperative Fluor Imaging Agent for the Detection of Peritoneal Mets
Conditions
Interventions
pegsitacianine
Locations
5
United States
Wake Forest Baptist Health
Winston-Salem, North Carolina, United States
The Ohio State University Wexner Medical Center / James Cancer Hospital
Columbus, Ohio, United States
Perelman School of Medicine, University of Pennsylvania
Philadelphia, Pennsylvania, United States
AHN Cancer Institute, West Penn Hospital
Pittsburgh, Pennsylvania, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Start Date
November 30, 2021
Primary Completion Date
December 29, 2022
Completion Date
January 20, 2023
Last Updated
November 8, 2024
NCT07001748
NCT06511037
NCT04107077
NCT05700656
NCT01617382
NCT04840264
Lead Sponsor
OncoNano Medicine, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions